Literature DB >> 25828130

Paclitaxel-eluting vs. bare metal stent implantation in saphenous vein graft lesions: Very long-term follow-up of the SOS (Stenting of Saphenous vein grafts) trial.

Alan Sosa1, Howard Chao1, Andres Guerra1, Henry Han1, Georgios Christopoulos1, Georgios E Christakopoulos1, Muhammad Nauman J Tarar1, James A de Lemos1, Owen Obel1, Tayo Addo1, Michele Roesle1, Donald Haagen1, Bavana V Rangan1, Subhash Banerjee1, Emmanouil S Brilakis2.   

Abstract

Entities:  

Keywords:  BMS, bare-metal stent(s); DES, drug-eluting stent(s); PES, paclitaxel-eluting stent(s); SVG, saphenous vein graft

Mesh：

Substances：

Year:  2015        PMID： 25828130     DOI： 10.1016/j.ijcard.2015.03.267

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  2 in total

1.  Rationale and design of the Drug-Eluting Stents vs Bare-Metal Stents in Saphenous Vein Graft Angioplasty (DIVA) Trial.

Authors:  Emmanouil S Brilakis; Subhash Banerjee; Robert Edson; Kendrick Shunk; Steven Goldman; David R Holmes; Deepak L Bhatt; Sunil V Rao; Mark W Smith; Mike Sather; Cindy Colling; Biswajit Kar; Lori Nielsen; Todd Conner; Todd Wagner; Bavana V Rangan; Beverly Ventura; Ying Lu; Mark Holodniy; Mei-Chiung Shih
Journal:  Clin Cardiol       Date:  2017-08-25       Impact factor: 2.882

Review 2.  The short- and long-term outcomes of percutaneous intervention with drug-eluting stent vs bare-metal stent in saphenous vein graft disease: An updated meta-analysis of all randomized clinical trials.

Authors:  Babikir Kheiri; Mohammed Osman; Ahmed Abdalla; Sahar Ahmed; Ghassan Bachuwa; Mustafa Hassan
Journal:  Clin Cardiol       Date:  2018-05-11       Impact factor: 2.882
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.